General information
AiCuris Anti-infective Cures AG
Friedrich-Ebert-Str. 475
Building 302
42117 Wuppertal, North Rhine-Westphalia
Germany
Contact person: Holger Zimmermann, Chief Executive Officer
Company main phone: +49 (202) 317630
Company main fax: +49 (202) 317631177
Website: https://www.aicuris.com
Year founded: | 2006
|
Source of foundation: | Spin-off from company |
Name of foundation source: | Bayer Infection Research |
Corporate description / mission:
AiCuris is a pharmaceutical company focused on the discovery, research and development of antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.The company’s first product, Letermovir (Prevymis®) is a therapy for human cytomegalovirus (HCMV) infections.
State of ownership: Private / independent
Headquarters: Yes
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Anti-infectives
- Proteins
- Small molecules
|
Primary therapeutic areas: |
- Infectious and parasitic diseases / infectiology / parasitology
|
Business model: |
- In-licensing
- Out-licensing
- R&D
|
Customer segments: |
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 4 | |
Phase I: | 2 | |
Phase III: | 3 | |
On the market: | 1 | |
Description of products:
Products:
Prevymis® / Letermovir (AIC246)
Pritelivir (AIC316)
Artilysins®, etc.
Collaborations & Clients
Partnering strategy / collaborations:
Merck & Co.
Royalty Pharma
Hybridize Therapeutics
Lysando